Daiichi Sankyo presents pivotal data from triple combination antihypertensive
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo's triple combination antihypertensive met its primary endpoint in a pivotal trial, show data presented this week at the American Society of Hypertension meeting in New York. CS-8635 (olmesartan plus hydrochlorothiazide plus amlodipine), which combines an angiotensin II receptor blocker, a diuretic and a calcium channel blocker, was filed last year in both the EU and the US.